NDC properties for "tobramycin (as tobramycin sulfate) 10 MG/ML Injectable Solution" (RxCUI 313416)
About this data
The tables show NDC propoerties for tobramycin (as tobramycin sulfate) 10 MG/ML Injectable Solution with the RxCUI 313416
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for tobramycin (as tobramycin sulfate) 10 MG/ML Injectable Solution (RxCUI 313416)
| ANDA | ANDA065122 |
|---|---|
| ANDA | ANDA209621 |
| MMSL_CODE | BD2850 |
| MMSL_CODE | CD2850 |
| RxCUI | 313416 |
| SPL_SET_ID | 645d34d9-275d-428e-863d-ae15ad009c44 |
| SPL_SET_ID | d6dd9460-b030-479a-b3e3-03606e6fcad1 |
| VUID | 4005549 |
| Prescribable Synonym | tobramycin 10 MG/ML Injectable Solution |
| RXNAV_STR | tobramycin 10 MG/ML Injectable Solution |
| RxNorm Name | tobramycin 10 MG/ML Injectable Solution |
| RxNorm Synonym | tobramycin (as tobramycin sulfate) 10 MG/ML Injectable Solution |
| Related queries | Interactions (for RxCUI 313416) |
NDC Properties
NDC Item 63323030501
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-01 |
| NDC Item | 63323030501 |
| Packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 63323-305 |
NDC Item 63323030502
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-02 |
| NDC Item | 63323030502 |
| Packaging | 25 VIAL, MULTI-DOSE in 1 TRAY (63323-305-02) / 2 mL in 1 VIAL, MULTI-DOSE (63323-305-01) |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 63323-305 |
NDC Item 68083025301
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-01 |
| NDC Item | 68083025301 |
| Packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 68083-253 |
NDC Item 68083025325
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-25 |
| NDC Item | 68083025325 |
| Packaging | 25 VIAL, MULTI-DOSE in 1 CARTON (68083-253-25) / 2 mL in 1 VIAL, MULTI-DOSE (68083-253-01) |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 68083-253 |
NDC Item 63323030501
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-01 |
| NDC Item | 63323030501 |
| Packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 63323-305 |
NDC Item 63323030502
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-02 |
| NDC Item | 63323030502 |
| Packaging | 25 VIAL, MULTI-DOSE in 1 TRAY (63323-305-02) / 2 mL in 1 VIAL, MULTI-DOSE (63323-305-01) |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 63323-305 |
NDC Item 68083025301
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-01 |
| NDC Item | 68083025301 |
| Packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 68083-253 |
NDC Item 68083025325
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-25 |
| NDC Item | 68083025325 |
| Packaging | 25 VIAL, MULTI-DOSE in 1 CARTON (68083-253-25) / 2 mL in 1 VIAL, MULTI-DOSE (68083-253-01) |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 68083-253 |
NDC Item 63323030501
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-01 |
| NDC Item | 63323030501 |
| Packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 63323-305 |
NDC Item 63323030502
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-02 |
| NDC Item | 63323030502 |
| Packaging | 25 VIAL, MULTI-DOSE in 1 TRAY (63323-305-02) / 2 mL in 1 VIAL, MULTI-DOSE (63323-305-01) |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 63323-305 |
NDC Item 68083025301
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-01 |
| NDC Item | 68083025301 |
| Packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 68083-253 |
NDC Item 68083025325
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-25 |
| NDC Item | 68083025325 |
| Packaging | 25 VIAL, MULTI-DOSE in 1 CARTON (68083-253-25) / 2 mL in 1 VIAL, MULTI-DOSE (68083-253-01) |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 68083-253 |
NDC Item 63323030501
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-01 |
| NDC Item | 63323030501 |
| Packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 63323-305 |
NDC Item 63323030502
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-02 |
| NDC Item | 63323030502 |
| Packaging | 25 VIAL, MULTI-DOSE in 1 TRAY (63323-305-02) / 2 mL in 1 VIAL, MULTI-DOSE (63323-305-01) |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 63323-305 |
NDC Item 68083025301
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-01 |
| NDC Item | 68083025301 |
| Packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 68083-253 |
NDC Item 68083025325
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-25 |
| NDC Item | 68083025325 |
| Packaging | 25 VIAL, MULTI-DOSE in 1 CARTON (68083-253-25) / 2 mL in 1 VIAL, MULTI-DOSE (68083-253-01) |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 68083-253 |